Although the role of the NLRP3 inflammasome in murine IBD models with NLRP3, ASC, or caspase-1 deficiency remains controversial (Siegmund et al., 2001; Allen et al., 2010; Bauer et al., 2010; Dupaul-Chicoine et al., 2010; Zaki et al., 2010; Bauer et al., 2012; Mao et al., 2018), inhibitors targeting the NLRP3 inflammasome, such as MCC950, oridonin, and INF39, have anti-inflammatory effects in colitis models (Chen et al., 2021). This evidence concerns the gene NLRP3 and inflammatory bowel disease.